Charles River Laboratories International Inc (CRL)
235.99
+0.70
(+0.30%)
USD |
NYSE |
May 09, 10:34
Charles River Laboratories International Enterprise Value: 14.51B for May 8, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 08, 2024 | 14.51B |
May 07, 2024 | 14.57B |
May 06, 2024 | 14.51B |
May 03, 2024 | 14.42B |
May 02, 2024 | 14.24B |
May 01, 2024 | 14.38B |
April 30, 2024 | 14.19B |
April 29, 2024 | 14.35B |
April 26, 2024 | 14.19B |
April 25, 2024 | 14.13B |
April 24, 2024 | 14.73B |
April 23, 2024 | 14.76B |
April 22, 2024 | 14.37B |
April 19, 2024 | 14.08B |
April 18, 2024 | 14.12B |
April 17, 2024 | 14.25B |
April 16, 2024 | 14.36B |
April 15, 2024 | 14.55B |
April 12, 2024 | 14.83B |
April 11, 2024 | 15.09B |
April 10, 2024 | 15.14B |
April 09, 2024 | 15.64B |
April 08, 2024 | 15.52B |
April 05, 2024 | 15.43B |
April 04, 2024 | 15.30B |
Date | Value |
---|---|
April 03, 2024 | 15.75B |
April 02, 2024 | 15.88B |
April 01, 2024 | 16.23B |
March 28, 2024 | 16.35B |
March 27, 2024 | 16.26B |
March 26, 2024 | 16.06B |
March 25, 2024 | 16.07B |
March 22, 2024 | 16.43B |
March 21, 2024 | 16.47B |
March 20, 2024 | 16.20B |
March 19, 2024 | 16.12B |
March 18, 2024 | 15.89B |
March 15, 2024 | 15.73B |
March 14, 2024 | 15.81B |
March 13, 2024 | 15.84B |
March 12, 2024 | 16.00B |
March 11, 2024 | 15.94B |
March 08, 2024 | 16.14B |
March 07, 2024 | 16.31B |
March 06, 2024 | 15.96B |
March 05, 2024 | 15.85B |
March 04, 2024 | 15.73B |
March 01, 2024 | 16.01B |
February 29, 2024 | 15.49B |
February 28, 2024 | 15.62B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
6.545B
Minimum
Mar 18 2020
25.61B
Maximum
Sep 24 2021
14.00B
Average
13.51B
Median
Dec 06 2022
Enterprise Value Benchmarks
Cardinal Health Inc | 25.87B |
Stryker Corp | 135.90B |
DaVita Inc | 22.40B |
IDEXX Laboratories Inc | 40.77B |
Medpace Holdings Inc | 11.60B |
Enterprise Value Related Metrics
Net Income (Quarterly) | 187.08M |
Revenue (Quarterly) | 1.013B |
Total Expenses (Quarterly) | 880.55M |
EPS Diluted (Quarterly) | 3.64 |
Gross Profit Margin (Quarterly) | 35.92% |
Profit Margin (Quarterly) | 18.46% |
Earnings Yield | 3.91% |
Operating Earnings Yield | 5.08% |
Normalized Earnings Yield | 3.911 |